Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937424 | 0.85 | MAPT (0.62) | MAPTL3MBTL1HTTKEAP1NFE2L2 | |
| SCHEMBL16572084 | 0.85 | L3MBTL1 (0.69) | MAPTL3MBTL1HTTKEAP1NFE2L2 | |
| SCHEMBL7604913 | 0.85 | HTT (0.65) | HTTKEAP1NFE2L2LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL937423 | 0.84 | MAPT (0.61) | MAPTL3MBTL1HTTKEAP1NFE2L2 | |
| SCHEMBL16804687 | 0.84 | L3MBTL1 (0.67) | MAPTL3MBTL1HTTKEAP1NFE2L2 | |
| SCHEMBL16572340 | 0.84 | L3MBTL1 (0.64) | MAPTL3MBTL1HTTKEAP1NFE2L2 | |
| SCHEMBL3797832 | 0.84 | L3MBTL1 (0.64) | MAPTL3MBTL1HTTKEAP1NFE2L2 | |
| SCHEMBL969073 | 0.83 | MAPT (0.63) | MAPTL3MBTL1HTTLMNASMN1; SMN2 | |
| SCHEMBL12176970 | 0.83 | HTT (0.67) | L3MBTL1HTTKEAP1NFE2L2LMNA | |
| SCHEMBL17086053 | 0.83 | L3MBTL1 (0.62) | MAPTL3MBTL1HTTKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663235-B1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2465852-A1 | Capped pyrazinoylguanidine sodium channel blockers | Parion Sciences, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7868010-B2 | N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible | PARION SCIENCES, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868010-B2 | N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible | PARION SCIENCES, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20090018144-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018144-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1663235-A4 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7410968-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1663235-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1656096-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | Parion Sciences, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20060052395-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20060052394-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050234072-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC., DURHAM, NC | 2005-10-20 | — | — | US | disclosed |
| US-20050228182-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034847-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080091-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| WO-2005018644-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | MAPT 1775/4885L3MBTL1 4335/4885HTT 886/4885 |
| US-20060052394-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | MAPT 1775/4885L3MBTL1 4335/4885HTT 886/4885 |
| US-20050080091-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | MAPT 1775/4885L3MBTL1 4335/4885HTT 886/4885 |
| US-20050234072-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | MAPT 1775/4885L3MBTL1 4335/4885HTT 886/4885 |
| US-20050228182-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | MAPT 1775/4885L3MBTL1 4335/4885HTT 886/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | MAPT 3864/4885L3MBTL1 1373/4885HTT 2397/4885 |
| US-20060052395-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | MAPT 1775/4885L3MBTL1 4335/4885HTT 886/4885 |
| US-20090018144-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCNN1B, SCNN1G, SCNN1A | MAPT 2501/4885L3MBTL1 4861/4885HTT 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.